1 CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute Cardiovascular Medicine Gill Heart Institute, Cardiovascular Medicine DISCLOSURES DISCLOSURES NOTHING TO DISCLOSE NOTHING TO DISCLOSE
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Gill Heart Institute Cardiovascular MedicineGill Heart Institute, Cardiovascular Medicine
DISCLOSURESDISCLOSURES
NOTHING TO DISCLOSENOTHING TO DISCLOSE
2
OBJECTIVESOBJECTIVES
Discuss the different diuretic regimens Discuss the different diuretic regimens th t il bl f ti t ithth t il bl f ti t iththat are available for patients with that are available for patients with decompensated heart failuredecompensated heart failure
Discuss methods for monitoring fluid Discuss methods for monitoring fluid status in patients with chronic systolicstatus in patients with chronic systolicstatus in patients with chronic systolic status in patients with chronic systolic heart failureheart failure
CASE #1CASE #1
34 year old male diagnosed with 34 year old male diagnosed with i h i di th i 2008i h i di th i 2008nonischemic cardiomyopathy in 2008nonischemic cardiomyopathy in 2008
–– LHC: no CADLHC: no CAD
–– LVEF 25%LVEF 25%
–– Placed on medical therapy including Placed on medical therapy including BB/ACEiBB/ACEi
In 2010 lost job/insurance and stopped In 2010 lost job/insurance and stopped all medications, physician followall medications, physician follow--upup
In late 2011 experienced increasing In late 2011 experienced increasing SOB, LE edema, orthopneaSOB, LE edema, orthopnea
3
CASE #1CASE #1
PE:PE:–– P 100 BP 96/60 Weight 340 lbsP 100 BP 96/60 Weight 340 lbs
Initiate intravenous diuresisInitiate intravenous diuresis–– IV bolus diuretic therapy IV bolus diuretic therapy
–– IV diuretic dripIV diuretic drip
UltrafiltrationUltrafiltration
ULTRAFILTRATIONULTRAFILTRATION
UNLOAD randomized 200 patients hospitalized with UNLOAD randomized 200 patients hospitalized with CHF to UF versus standard diureticsCHF to UF versus standard diureticsCHF to UF versus standard diureticsCHF to UF versus standard diuretics–– UF group: no diuretics; UF up to 48 hoursUF group: no diuretics; UF up to 48 hours
–– Standard group: IV diuretics at a dose twice that of home doseStandard group: IV diuretics at a dose twice that of home dose
–– Primary endpoint: Weight loss and objective dyspnea at 48 hrsPrimary endpoint: Weight loss and objective dyspnea at 48 hrs
Hemodialysis line placed in right IJ veinHemodialysis line placed in right IJ veinHemodialysis line placed in right IJ veinHemodialysis line placed in right IJ vein
Ultrafiltration initiated and titrated up to 250 mL/hour fluid Ultrafiltration initiated and titrated up to 250 mL/hour fluid removalremoval
Successful 10 L diuresis over 3 days with improvement Successful 10 L diuresis over 3 days with improvement in serum creatinine (1.8 to 1.3)in serum creatinine (1.8 to 1.3)
7
CASE #1CASE #1
Patient transitioned to IV diuretics, then oral diureticsPatient transitioned to IV diuretics, then oral diuretics–– Discharged on oral Bumex 2 mg bidDischarged on oral Bumex 2 mg bidDischarged on oral Bumex 2 mg bidDischarged on oral Bumex 2 mg bid
Chronic HF therapy optimized including ACEi, BB, and Chronic HF therapy optimized including ACEi, BB, and aldosterone antagonistaldosterone antagonist
6 months later:6 months later:N b t h it li tiN b t h it li ti–– No subsequent hospitalizationsNo subsequent hospitalizations
CASE #2CASE #2
41 year old with dilated cardiomyopathy (LVEF 15%) in 41 year old with dilated cardiomyopathy (LVEF 15%) in setting of HIV (dx 1994) referred by his cardiologist forsetting of HIV (dx 1994) referred by his cardiologist forsetting of HIV (dx 1994) referred by his cardiologist for setting of HIV (dx 1994) referred by his cardiologist for advanced heart failure optionsadvanced heart failure options
NYHA class IIINYHA class III--IV symptomsIV symptoms
Echo: LV moderately dilated (6.3 cm LVEDD); moderate Echo: LV moderately dilated (6.3 cm LVEDD); moderate MRMR
Rx: carvedilol 3.125 mg bid, lisinopril 2.5 mg qday, lasix Rx: carvedilol 3.125 mg bid, lisinopril 2.5 mg qday, lasix 40 mg qday and HAART40 mg qday and HAART40 mg qday, and HAART40 mg qday, and HAART
Admitted to periods of noncomplianceAdmitted to periods of noncompliance
Told me HIV viral load was “in the millions” and CD4 Told me HIV viral load was “in the millions” and CD4 count was “less than 50”count was “less than 50”
8
CASE #2CASE #2
Other hx included several AIDS defining illnesses:Other hx included several AIDS defining illnesses:–– PCP pneumoniaPCP pneumoniaPCP pneumoniaPCP pneumonia
–– MACMAC
–– CMV pneumonitisCMV pneumonitis
PE:PE:–– P 110 BP 100/60 Weight 130 lbsP 110 BP 100/60 Weight 130 lbs
–– Chronically ill appearing, cachectic; in wheelchairChronically ill appearing, cachectic; in wheelchair
–– HEENT: JVP 12 cm H20HEENT: JVP 12 cm H20HEENT: JVP 12 cm H20HEENT: JVP 12 cm H20
–– Lungs ClearLungs Clear
–– CV: tachycardic with S3 gallop and 2/6 MR murmurCV: tachycardic with S3 gallop and 2/6 MR murmur
Are HIV/AIDS absolute contraindications to heart Are HIV/AIDS absolute contraindications to heart transplantation and/or VAD placement?transplantation and/or VAD placement?transplantation and/or VAD placement?transplantation and/or VAD placement?
Is upIs up--titration of medical therapy and ICD placement his titration of medical therapy and ICD placement his only option?only option?
How much is noncompliance playing a role in his poor How much is noncompliance playing a role in his poor functional status, failure to thrive?functional status, failure to thrive?
9
LVAD IN HIV PATIENTSLVAD IN HIV PATIENTS
Sims DB et al. J Heart Lung Transplant 2011;30:1060-4
HEART TX IN HIV PATIENTSHEART TX IN HIV PATIENTS
Uriel N et al. J Heart Lung Transplant 2009;28:667-9
All patients had negative HIV viral load at time of transplant
10
CASE #2CASE #2
Decided to obtain right heart catheterization as Decided to obtain right heart catheterization as outpatientoutpatientoutpatientoutpatient
Before RHC was obtained, patient presented with Before RHC was obtained, patient presented with decompensated heart failure and transferred to UKdecompensated heart failure and transferred to UK
Did well with diuresis, but hospitalization complicated by Did well with diuresis, but hospitalization complicated by mental status changes, elevated LFTs, and mental status changes, elevated LFTs, and thrombocytopenia (20K)thrombocytopenia (20K)
CASE #2CASE #2
RHC:RHC:–– CVP 10 mm HgCVP 10 mm HgCVP 10 mm HgCVP 10 mm Hg
–– RV 38/10RV 38/10
–– PA 38/22 (28 mm Hg)PA 38/22 (28 mm Hg)
–– PCWP 20 mm HgPCWP 20 mm Hg
–– CO 4.2 L/min; CI 2.4 L/min/m2CO 4.2 L/min; CI 2.4 L/min/m2
Plan: outpatient f/u with titration of medical therapyPlan: outpatient f/u with titration of medical therapy
11
CASE #2CASE #2
Patient started to improve over next 2 monthsPatient started to improve over next 2 months–– More compliant with HAARTMore compliant with HAART –– improving CD4 count andimproving CD4 count andMore compliant with HAART More compliant with HAART improving CD4 count and improving CD4 count and
dropping viral loaddropping viral load
–– Improving appetite and muscle strength (started to gain weight)Improving appetite and muscle strength (started to gain weight)
–– Remained class III HF but less problems with LE edemaRemained class III HF but less problems with LE edema
–– Baseline HR improved to 80s (from 100s) and was able to tolerat Baseline HR improved to 80s (from 100s) and was able to tolerat upup--titration of beta blockertitration of beta blocker
Another RHC obtained with similar results as previousAnother RHC obtained with similar results as previous
Eventually was able to lower his diuretic from lasix 80 Eventually was able to lower his diuretic from lasix 80 mg bid to 40 mg bidmg bid to 40 mg bid
HOWEVER….HOWEVER….
One month later…(around New Years..)One month later…(around New Years..)–– Felt fatigued and had a few episodes of nausea/emesisFelt fatigued and had a few episodes of nausea/emesisFelt fatigued, and had a few episodes of nausea/emesisFelt fatigued, and had a few episodes of nausea/emesis
–– Noted lower urine output and increased his lasix from 40 bid to Noted lower urine output and increased his lasix from 40 bid to 80 bid80 bid
–– Fatigue worsened and some orthostatic symptomsFatigue worsened and some orthostatic symptoms
Seen in clinic and appeared drySeen in clinic and appeared dry
Labs: Sodium 119; BUN 50; Cr 2.2Labs: Sodium 119; BUN 50; Cr 2.2
Admitted to hospital for IV hydration with improvement in Admitted to hospital for IV hydration with improvement in BMPBMP
12
NEXT STEP?NEXT STEP?
HF appeared to have stabilized to point where LVAD HF appeared to have stabilized to point where LVAD was not neededwas not neededwas not neededwas not needed
Despite patient education/instruction, he seemed Despite patient education/instruction, he seemed particularly prone to episodes of fluid overload and particularly prone to episodes of fluid overload and dehydration with need to adjust diuretic therapydehydration with need to adjust diuretic therapy
Complicating matters was his increasing weight due to Complicating matters was his increasing weight due to improvement in muscle mass, appetiteimprovement in muscle mass, appetite
Is there another way to track his fluid status?Is there another way to track his fluid status?
Ritzema J et al. Circ 2007;116:2952-9
13
LA PRESSURE MONITORINGLA PRESSURE MONITORING
LA pressures can be LA pressures can be transmitted totransmitted totransmitted to transmitted to clinician dailyclinician dailyAdjustments can be Adjustments can be made to made to medications before medications before clinical symptoms clinical symptoms ariseariseariseariseSafety/utility seen in Safety/utility seen in pilot study of 8 pilot study of 8 patientspatients
Ritzema J et al. Circ 2007;116:2952-9
LAPTOPLAPTOP--HFHF
LAPTOPLAPTOP--HF is a prospective, multiHF is a prospective, multi--center, randomized center, randomized study assessing benefit of LA pressure monitoring study assessing benefit of LA pressure monitoring y g p gy g p gsystemsystem
Randomization 1:1 toRandomization 1:1 to–– sensor implanted providing ongoing LAP readings to the hand held sensor implanted providing ongoing LAP readings to the hand held
along with physician prescribed medication recommendations along with physician prescribed medication recommendations OROR
–– no sensor implant but a handno sensor implant but a hand--held device for medication remindersheld device for medication reminderspp
UK is a participating institution and actively enrollingUK is a participating institution and actively enrolling